T1N0乳腺癌免腋窝手术与腋窝分期20年随访:INT 09/98随机临床试验
INT 09/98试验纳入565例65岁以下T1N0乳腺癌患者,随机比较单纯象限切除(QU)与象限切除加腋窝清扫(QUAD),中位随访20年显示两组总生存(OS)调整风险比1.18(P=0.326)、无病生存(DFS)调整风险比1.27(P=0.280),均在预设非劣效界值内。QU组腋窝复发率低,避免腋窝手术及减少辅助治疗未增加远处转移或影响长期生存。
要点
- T1N0乳腺癌省略腋窝手术在20年随访中未显示OS或DFS劣于腋窝清扫。
- QU组腋窝复发率低,仅部分转移淋巴结会导致复发。
- QU组中生物学特征良好但腋窝淋巴结状态未知者未接受辅助化疗,结局无显著差异。
核心结论
- 避免腋窝手术并减少辅助治疗在早期乳腺癌中不增加远处转移或影响长期生存。
- QU和QUAD组中腋窝复发伴远处转移的患者可能代表基因组决定预后较差,与手术干预和辅助治疗无关。
研究设计与样本
- INT09/98随机临床试验探索65岁以下早期乳腺癌省略腋窝手术。
- 1998年6月至2003年6月共入组565例T1N0乳腺癌患者,检验单纯象限切除(QU)对比象限切除加腋窝清扫(QUAD)的非劣效性。
- 主要终点为总生存(OS),次要终点包括无病生存(DFS)及QU组腋窝淋巴结转移发生率/时间。
主要发现
- 20年随访显示QU与QUAD组无显著差异,OS调整风险比1.18(P=0.326),DFS调整风险比1.27(P=0.280),均在预设非劣效界值内。
- QU组腋窝复发率保持低水平,表明仅部分转移淋巴结在未切除时会导致复发。
- QU组中生物学特征良好但腋窝淋巴结状态未知者未接受辅助化疗,结局无显著差异。
- QU和QUAD组腋窝复发伴远处转移率相似,可能反映原发肿瘤侵袭性生物学。
关键数值与推荐
- 非劣效性界值原文未具体报告。
临床怎么用
- 对于T1N0早期乳腺癌,可考虑省略腋窝手术分期,但需结合生物学特征个体化决策。
- 生物学特征良好但腋窝状态未知者,省略辅助化疗可能不影响结局,需谨慎选择。
局限性
- 原文未具体报告非劣效界值数值。
- 原文未报告样本量以外的其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The role of axillary surgery in breast cancer has shifted over time from a therapeutic operation to a staging method for subsequent adjuvant therapies, through the introduction of sentinel lymph node biopsy. The discovery of molecular subtypes has since questioned the necessity of axillary staging in breast cancer. METHODS: The INT09/98 randomized trial explored the omission of axillary surgery in early-stage breast cancer in patients under 65 years of age. From June 1998 to June 2003, a total of 565 T1N0 breast cancer patients were enrolled. The trial tested the non-inferiority of quadrantectomy without axillary surgery (QU) compared to quadrantectomy with axillary dissection (QUAD). The primary endpoint was overall survival (OS). Secondary endpoints included disease-free survival (DFS) and incidence/timing of axillary lymph node metastasis in the QU arm. RESULTS: Follow-up at 20 years showed no significant differences between the QU versus the QUAD arm. The adjusted hazard ratio for OS was 1.18 (P = 0.326) and DFS was 1.27 (P = 0.280) respectively, both within the predetermined non-inferiority limit. Axillary relapse rates in the QU arm remained low, indicating that only a subset of metastatic nodes cause recurrences if not removed. In the QU arm, patients with favourable biological features but unknown axillary node involvement did not receive adjuvant chemotherapy, without significant differences in outcomes. The axillary relapse rate with distant metastases was similar in both arms and may reflect aggressive biology of the primary tumour. CONCLUSION: Avoiding axillary surgery and reducing adjuvant treatments in early breast cancer does not increase distant metastases or affect long-term survival. Axillary relapsed patients with distant metastases in both QU and QUAD arms may represent cancers with genomically determined poorer prognosis, independent of surgical intervention and adjuvant therapies. REGISTRATION NUMBER: NCT01508546 (http://www.clinicaltrials.gov).
引用
- Agresti R, Sandri M, Capri G, et al. Axillary surgery versus no-axillary staging in T1N0 breast cancer: 20-year follow-up of the INT 09/98 randomized clinical trial. Br J Surg. 2025. PMID: 40042985. doi:10.1093/bjs/znae311
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。